InvestorsHub Logo
Followers 14
Posts 456
Boards Moderated 0
Alias Born 04/07/2013

Re: None

Friday, 09/04/2020 11:46:45 PM

Friday, September 04, 2020 11:46:45 PM

Post# of 422623
HAMOA + NORTH + ATTORNEYS:

Could you please shoot me back your thoughts on my Posts and Position on the subject below?

It's NOT about the secondary considerations!

Singer kept saying over and over that Mori (BAD evidence) "Bled-over" to the weighing of the secondary considerations! (Meaning the Secondary Considerations would take on a whole new meaning if Mori was recognized as flawed!) They kept asking about the Secondary Considerations and they kept saying: Explain what you mean about bleeding over!!!!!! He couldn't get them to understand that Mori was flawed!

If he said: Novo allows "But/If" information meaning: Your Honor: The Secondary Considerations would have been ok BUT/IF Mori wasn't intentionally chopped!!!

I don't think anyone gets it!

The secondary consideration issue got us to the dance-floor!

To make it clearer: Please read my posting #296183 in full...

He kept saying over and over and over: Do not miss my point about the Mori Evidence which Du based her case on that was not accurate.

They weren't hearing him YET the Appeals Judges for Novo did! Didn't Novo make it to the US Supreme Court?? They heard it too!

This Precedent Setting Case clearly states that they would have viewed the Secondary Considerations differently if they had Evidence that was intentionally abused...

THAT IS THE DOOR TO A SUCCESSFUL APPEAL YET SINGER DIDN'T USE THE NOVO REFERNCE! THEY ASKED: GIVE US SOMETHING!

They didn't hear him YET had he referenced Novo (see my posting - the Novo reference is there), they would have gotten it!

Because they ONLY focused on the Secondary Considerations, they failed to review the Appeal as a whole!

En Banc could work if he just shoves the Novo reference down their throat!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158104831
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News